metricas

Vacunas

Sugerencias
Vacunas Effectiveness of the vaccine (Covaxin®) on different age groups of people: A pi...
Información de la revista
Vol. 25. Núm. 2.
Páginas 149-288 (Abril - Junio 2024)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1433
Vol. 25. Núm. 2.
Páginas 149-288 (Abril - Junio 2024)
Original article

Effectiveness of the vaccine (Covaxin®) on different age groups of people: A pilot study

Efectividad de la vacuna (Covaxin®) en los diferentes grupos de edad de las personas: Estudio piloto
Visitas
1433
Vivek Chauhana, Adrija Rakshita, Vivek Kumar Dhimana,b, Gaytri Mahajana, Akash Pnadeya, Shamsher Singh Kanwara,
Autor para correspondencia
kanwarss2000@yahoo.com

Corresponding authors.
, Devendra Singhc,
Autor para correspondencia
devendrasingh.ibst@srmu.ac.in

Corresponding authors.
a Department of Biotechnology, Himachal Pradesh University, Shimla 171005, India
b Department of Biotechnology, Dr. YSP UHF, Nauni, Solan 173230, India
c Faculty of Biotechnology, Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Barabanki 225003, Uttar Pradesh, India
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
COVID-19: impacto de la Vacuna - COVID-19: Vaccine impact

Editado por: Dra. Núria Torner CIBER Epidemiologia y Salud Publica CIBERESP Unitat de Medicina Preventiva i Salut Pública Departament de Medicina, Universitat de Barcelona

Última actualización: Julio 2024

Más datos
Abstract
Background

Covaxin® is a COVID-19 vaccine created and produced by Bharat Biotech in India. The vaccine is based on the strain of SARS-CoV-2 that was first identified in India and has undergone Phase III clinical trials. Covaxin® has been authorized for emergency use in India and has been distributed as part of India's vaccination campaign. The vaccine has been shown to be effective in preventing COVID-19 infection and hospitalization, but additional studies are needed to determine its efficacy as well as safety in the long term.

Methods

The antibody titer against Covaxin® was detected through indirect ELISA immunoassay. Optimization was performed on 500 samples to get an idea and work further on a larger number of samples.

Results

The vaccine had the best immune response in individuals between the ages of 21 and 30 and the least response in those between 61 and 70. This was attributed to the phenomenon of immunosenescence, which explains the weakening of the immune system with age. Additionally, the study found that the equine anti-CoV-19 serum had a higher binding affinity with Covaxin®, highlighting the effectiveness of horse Ig against COVID-19 antigens.

Conclusions

The study concluded that Covaxin® was effective in generating an immune response in individuals after 2 doses of vaccination; however, the generated immune response decreased with the time of vaccine administration and the age of the vaccinated. The study also showed that the ELISA technique used in this research is an efficient and sensitive method to evaluate vaccine efficiency and can be applied to a larger number of samples for further comparative analysis.

Keywords:
COVID-19
SARS-CoV-2
Vaccine
Covaxin
Palabras clave:
COVID-19
SARS-CoV-2
Vacuna
Covaxin
Resumen
Antecedentes

Covaxin® es una contra la COVID-19 creada y producida por Bharat Biotech en India. Dicha vacuna se basa en la cepa de SARS-CoV-2 inicialmente identificada en India, habiéndose sometido a los ensayos clínicos de Fase III. Covaxin® ha sido autorizada para uso urgente en India, habiéndose distribuido como parte de la campaña de vacunación en el país. Ha demostrado ser efectiva para la prevención de la infección y hospitalización por COVID-19, pero son necesarios estudios adicionales para determinar su eficacia, así como su seguridad a largo plazo.

Métodos

El título de anticuerpos contra Covaxin® fue detectado mediante inmunoensayo ELISA indirecto. La optimización fue realizada en 500 muestras, para adquirir una idea y trabajar adicionalmente en un número mayor de muestras.

Resultados

La vacuna reflejó la mejor respuesta inmune en individuos de entre 21 y 30 años de edad, y la menor respuesta en personas de entre 61 y 70 años. Esto se atribuyó al fenómeno de inmunosenescencia, que explica el debilitamiento del sistema inmune con la edad. Además, el estudio encontró que el suero equino anti-CoV-19 tenía una mayor afinidad de unión a Covaxin®, lo cual subraya la efectividad del Ig equino contra los antígenos de COVID-19.

Conclusiones

El estudio concluyó que Covaxin® fue efectiva para generar una respuesta inmune en los individuos, tras la administración de dos dosis de vacunación. Sin embargo, la respuesta inmune generada disminuyó con el tiempo transcurrido desde la administración de la vacuna y la edad de las personas vacunadas. El estudio reflejó también que la técnica ELISA utilizada en esta investigación fue un método eficiente y sensible para evaluar la eficiencia vacunal, pudiendo aplicarse a un número de muestras mayor, de cara a un análisis comparativo adicional.

Artículo

Opciones para acceder a los textos completos de la publicación Vacunas
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
References
[1.]
D. Singh, V. Agarwal.
A review on the COVID-19, its history, diagnostic approaches, role of herbs and current world scenario.
Biomed, 41 (2021), pp. 328-332
[2.]
N. Zaki, E.A. Mohamed.
The estimations of the COVID-19 incubation period: a scoping reviews of the literature.
J Infect Public Health, 14 (2021), pp. 638-646
[3.]
H. Zhao, X. Lu, Y. Deng, Y. Tang, J. Lu.
COVID-19: asymptomatic carrier transmission is an underestimated problem.
Epidemiol Infect, 148 (2020),
[4.]
S.P. Kaur, V. Gupta.
COVID-19 vaccine: a comprehensive status report.
[5.]
P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, et al.
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature, 579 (2020), pp. 270-273
[6.]
J. Quarleri, V. Galvan, M.V. Delpino.
The Omicron variant of the SARS-CoV-2 is a quest to define the consequences of its high mutational load.
Springer, (2022), pp. 1-4
[7.]
M. D'Arienzo, A. Coniglio.
Assessment of the SARS-CoV-2 basic reproduction number, R (0), based on the early phase of the COVID-19 outbreak in Italy.
Biosaf Health, 2 (2020), pp. 57-59
[8.]
R. Ella, S. Reddy, H. Jogdand, V. Sarangi, B. Ganneru, S. Prasad, et al.
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomized controlled trial) and the persistence of immune responses from a phase 1 follow-up report.
medRxiv, 2020 (2020), pp. 12
[9.]
M. Voysey, S.A.C. Clemens, S.A. Madhi, L.Y. Weckx, P.M. Folegatti, P.K. Aley, et al.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK.
[10.]
V. Chauhan, D. Kaushal, V.K. Dhiman, S.S. Kanwar, D. Singh, V.K. Dhiman, H. Pandey.
An insight in developing carrier-free immobilized enzymes.
Front Bioeng Biotechnol, 10 (2022),
[11.]
S. Sakamoto, W. Putalun, S. Vimolmangkang, W. Phoolcharoen, Y. Shoyama, H. Tanaka, et al.
Enzyme-linked immunosorbent assay for the quantitative/qualitative analysis of plant secondary metabolites.
J Nat Med, 72 (2018), pp. 32-42
[12.]
D. Singh, V. Singh, S.B. Mishra, D. Sharma, V. Agarwal.
Evaluation of anti-biofilm, anti- quorum, the anti-dysenteric potential of designed polyherbal formulation: in vitro and in vivo study.
J Appl Biomed, 20 (2022), pp. 7-14
[13.]
V. Chauhan, S.S. Kanwar.
Lipopeptide (s) associated with the human microbiome as a potent cancer drug.
Seminars in Cancer Biology, pp. 128-133
[14.]
P. Hornbeck.
Enzyme-linked immunosorbent assays.
Curr Protoc Immunol, 1 (1992),
[15.]
D.M. Mason, S. Friedensohn, C.R. Weber, C. Jordi, B. Wagner, S.M. Meng, et al.
Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning.
Nat Biomed Eng, 5 (2021), pp. 600-612
[16.]
C. Giefing-Kröll, P. Berger, G. Lepperdinger, B. Grubeck-Loebenstein.
How sex and age affect immune responses, susceptibility to infections, and response to vaccination.
Aging Cell, 14 (2015), pp. 309-321
[17.]
L.E.R. Cunha, A.A. Stolet, M.A. Strauch, V.A.R. Pereira, C.H. Dumard, A.M.O. Gomes, et al.
Polyclonal F(ab')(2) fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency.
[18.]
S. Najjar, A. Najjar, D.J. Chong, B.K. Pramanik, C. Kirsch, R.I. Kuzniecky, et al.
Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports.
J Neuroinflammation, 17 (2020), pp. 231
[19.]
R.D. Kovaiou, D. Herndler-Brandstetter, B. Grubeck-Loebenstein.
Age-related changes in immunity: implications for vaccination in the elderly.
Expert Rev Mol Med, 9 (2007), pp. 1-17
[20.]
S. Agarwal, P.J. Busse.
Innate and adaptive immunosenescence.
Ann Allergy Asthma Immunol, 104 (2010), pp. 183-190
[21.]
D. Alfego, A. Sullivan, B. Poirier, J. Williams, D. Adcock, S. Letovsky.
A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.
[22.]
B. Gourbal, S. Pinaud, G.J.M. Beckers, J.W.M. Van Der Meer, U. Conrath, M.G. Netea.
Innate immune memory: an evolutionary perspective.
Immunol Rev, 283 (2018), pp. 21-40
[23.]
D. Singh, V. Agarwal.
Herbal antibacterial remedy against upper respiratory infection causing bacteria and in vivo safety analysis.
Vegetos, 35 (2022), pp. 264-268
[24.]
D. Singh, D. Sharma, V. Agarwal.
Screening of anti-microbial, anti-biofilm activity, and cytotoxicity analysis of a designed polyherbal formulation against shigellosis.
J Ayurveda Integr Med., 12 (2021), pp. 601-606
[25.]
D. Singh, V. Agarwal.
Screening of antimicrobial, anti-quorum sensing activity and cytotoxicity of origanum oil against Gram-positive and Gram-negative bacteria.
Biomedicine., 41 (2021), pp. 599-603
[26.]
D. Singh, V. Agarwal.
An in vivo acute toxicity and anti-shigellosis effect of designed formulation on rat.
J Ayurveda Integr Med, 14 (2023),
[27.]
C.A. Janeway Jr..
How the immune system protects the host from infection.
Microbes Infect, 3 (2001), pp. 1167-1171
[28.]
A.E. Palm, C. Henry.
Remembrance of things past: long-term B cell memory after infection and vaccination.
Front Immunol, 10 (2019), pp. 1787
[29.]
U. Sahin, A. Muik, E. Derhovanessian, I. Vogler, L.M. Kranz, M. Vormehr, et al.
COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses.
Nature, 586 (2020), pp. 594-599
[30.]
G. Milne, T. Hames, C. Scotton, N. Gent, A. Johnsen, R.M. Anderson, et al.
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?.
Lancet Respir Med, 9 (2021), pp. 1450-1466
[31.]
G. León, M. Herrera, M. Vargas, M. Arguedas, A. Sánchez, Á. Segura, et al.
Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.
bioRxiv, 2020 (2020), pp. 10
asdasdasd
Opciones de artículo
Herramientas